Back to top

Image: Bigstock

Orexigen Therapeutics, Inc.

Read MoreHide Full Article

Orexigen’s fourth quarter results were disappointing with the company missing on revenues and posting a wider-than-expected loss. Contrave scrips slipped 2.2% sequentially during the quarter. The company's dependence on Contrave for growth and lack of pipeline candidates is concerning. Contrave is facing additional competition in the form of Saxenda as well as a patent challenge. Moreover, while encouraged by the company’s plans to boost Contrave sales through a more targeted approach, we note that driving growth in the branded obesity segment remains challenging and executions risks remain. We are also concerned about the termination of the new CV outcomes study. Meanwhile, Orexigen is currently in discussions with potential partners for additional regions.

Published in